Lifescience database of Cancer in India

Sunday, 3 November 2013

Top 10 Best-selling Cancer Drugs 2012

  • Rituxan - $3 billion
  • Avastin - $2.66 billion
  • Herceptin - $1.66 billion
  • Gleevec - $1.51 billion
  • Eloxatin - $1.2 billion
  • Alimta - $1.04 billion
  • Erbitux - $703.3 million
  • Velcade - $692.7 million
  • Xeloda - $647.6 million
  • Tarceva - $564.2 million

    • Source:     http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs/top-10-best-selling-cancer-drugs
    Posted by Lifescience Database of Cancer in India at 21:54
    Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

    No comments:

    Post a Comment

    Newer Post Older Post Home
    Subscribe to: Post Comments (Atom)

    Popular Posts

    • New Data from Sanjay Gandhi Post Graduate Institute of Medical Science Illuminate Findings in Gallbladder Cancer
      Current study results on Oncology have been published. According to news reporting originating from  Uttar Pradesh, India , by VerticalNews...
    • Apollo Hospitals to Host International Forum on Battling Cancer - Moneylife
      Apollo Hospitals to Host International Forum on Battling Cancer - Moneylife
    • Oncology 'win' for Mildura: Appointment of Dr Divy will mean treatment closer to home
      IN a first for Sunraysia, Mildura Base Hospital has secured the services of a resident oncologist. Dr Divyanshu Dua started in the role ...
    • GSK-Dr Reddy’s alliance to register their first product in 2014
      GSK refuses to name the product or the therapeutic segment it falls under   GlaxoSmithKline Plc  ( GSK ) and  Dr. Reddy’s  Laboratories ...
    • Max Healthcare, GE Healthcare sign partnership agreement to advance standard of cancer care in India
      Max Healthcare, a leading healthcare services provider and GE Healthcare, have inked a   strategic partnership to advance the standard...
    • Oncology Drugs Approved by USFDA in 2013
      Gilotrif (afatinib) ; Boehringer Ingelheim; For the treatment of metastatic non-small cell lung cancer with EGFR mutations, Approved July ...
    • Merck Serono Israel incubator nurtures early stage projects
      Germany’s Merck KgaA (XETRA: MRK) unit Merck Serono is one of the most active healthcare corporations in Israel. The company, which has all...
    • MSD's Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
      MSD's Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma ...
    • ‘Oncology is the new Cardiology in India’
      ‘Oncology is the new Cardiology in India’ India has a success history in cardiology so far. Oncology care is still finding it...
    • Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
      Merck Also to Initiate Phase I "Signal Finding" Study with MK-3475 in 20 New Cancer Types WHITEHOUSE STATION, N.J.--(BUSINESS W...

    Blog Archive

    • ►  2015 (88)
      • ►  May (1)
      • ►  April (15)
      • ►  February (17)
      • ►  January (55)
    • ►  2014 (379)
      • ►  December (82)
      • ►  November (25)
      • ►  October (42)
      • ►  September (26)
      • ►  August (21)
      • ►  July (8)
      • ►  June (27)
      • ►  May (25)
      • ►  April (38)
      • ►  March (31)
      • ►  February (31)
      • ►  January (23)
    • ▼  2013 (68)
      • ►  December (27)
      • ▼  November (41)
        • HPV testing can reduce by a third incidence of cer...
        • Sanofi, Merrimack rack up third straight failure f...
        • FDA official talks up new review approach
        • Drug developer Compugen sees boost from Bayer onco...
        • Mithra seeks distribution partners in India
        • Biocon-Mylan's drug to treat breast cancer to come...
        • Indian, Nepalese hospitals tie up for cancer treat...
        • Mylan-Biocon Receive First Indian Biosimilar Regul...
        • Arrayit Corporation To Work With Diagnostic Oncolo...
        • Roche Gets EU Approval for Breast Cancer Drug
        • Narayana Health Launches Rural Cancer Surveillance...
        • Pfizer's XALKORI(R) Granted Regular FDA Approval S...
        • NEXAVAR tablets receive FDA approval for treatment...
        • Cadila Pharma announces launch of innovative drug ...
        • Timely tests can cut cervical cancer by a third: E...
        • Reports Outline Thyroid Cancer Study Findings from...
        • Breast cancer on rise in Assam
        • Oncoplastic surgery replacing mastectomy in breast...
        • FDA approves Imbruvica for rare blood cancer
        • New Data from Sanjay Gandhi Post Graduate Institut...
        • Merck Enters into Further Global Co-Development an...
        • Conference on women’s imaging in oncology in Coimb...
        • New drug could potentially treat lung cancer
        • India sees 1.3Lakh breast cancer cases annually
        • Japanese company prices breast cancer drug in tier...
        • FDA Approves Abraxane for Metastatic Pancreatic Ca...
        • Subscription for doctors profile in India in Oncology
        • NewsLetter Subscription
        • Cancer Awareness Day: NGO, corporate house join ha...
        • Best Oncology Hospitals in India 2012
        • Top 10 Late-Stage Cancer Drugs – 2012
        • Top 10 Best-selling Cancer Drugs 2012
        • News Letter Subscription
        • Only 25% paediatric cancers cured every year in India
        • Laboratory testing kit that estimates risk of brea...
        • Patented Products approved in India 2012-2013
        • Oncology Drugs Approved by USFDA 1995-2012
        • Oncology Drugs Approved by USFDA in 2013
        • FDA Approves Cancer Fighting Drug 'Gazyva' From Roche
        • Patient Support Groups in India
        • Association of Oncologists in India

    Total Pageviews

    About Me

    Lifescience Database of Cancer in India
    View my complete profile
    Simple theme. Powered by Blogger.